Cargando…

Natural Products with Toll-Like Receptor 4 Antagonist Activity

Toll-Like Receptors (TLRs) are the innate immunity receptors that play an activating role when interacting with molecules released by bacteria and viruses (PAMPs, pathogen-associated molecular patterns) or with molecules released by injured cells and tissues (DAMPs, danger-associated molecular patte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Molteni, Monica, Bosi, Annalisa, Rossetti, Carlo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5852877/ https://www.ncbi.nlm.nih.gov/pubmed/29686833 http://dx.doi.org/10.1155/2018/2859135

Ejemplares similares

The Role of Toll-Like Receptor 4 in Infectious and Noninfectious Inflammation
por: Molteni, Monica, et al.
Publicado: (2016)

The Effect of Cyanobacterial LPS Antagonist (CyP) on Cytokines and Micro-RNA Expression Induced by Porphyromonas gingivalis LPS
por: Molteni, Monica, et al.
Publicado: (2018)

MiR-146a induction by cyanobacterial lipopolysaccharide antagonist (CyP) mediates endotoxin cross-tolerance
por: Molteni, Monica, et al.
Publicado: (2018)

Toll-like receptor 4 (TLR4) antagonists as potential therapeutics for intestinal inflammation
por: Tam, Janine S. Y., et al.
Publicado: (2021)

A cyanobacterial LPS antagonist prevents endotoxin shock and blocks sustained TLR4 stimulation required for cytokine expression
por: Macagno, Annalisa, et al.
Publicado: (2006)

Saturation of acyl chains converts cardiolipin from an antagonist to an activator of Toll-like receptor-4
por: Pizzuto, Malvina, et al.
Publicado: (2019)

Toll-like receptor 4 in atherosclerosis
por: Li, Hongli, et al.
Publicado: (2007)

Lack of Effects of Toll-Like Receptor 4 Antagonists on the Reinforcing Effects of Cocaine and Remifentanil
por: Hiranita, Takato
Publicado: (2016)

Toll-Like Receptor 4 Activation in Cancer Progression and Therapy
por: Oblak, Alja, et al.
Publicado: (2011)

The Toll-like receptor 4 antagonist TAK-242 protects against chronic pancreatitis in rats
por: Pan, Long-Fei, et al.
Publicado: (2017)

The Toll-Like Receptor 4 Antagonist Eritoran Protects Mice from Lethal Filovirus Challenge
por: Younan, Patrick, et al.
Publicado: (2017)

Modeling of the Toll-like receptor 3 and a putative Toll-like receptor 3 antagonist encoded by the African swine fever virus
por: Henriques, Elsa S, et al.
Publicado: (2011)

Toll-Like Receptors in Natural Killer Cells and Their Application for Immunotherapy
por: Noh, Ji-Yoon, et al.
Publicado: (2020)

Discovery and Development of Toll-Like Receptor 4 (TLR4) Antagonists: A New Paradigm for Treating Sepsis and Other Diseases
por: Leon, Carlos G., et al.
Publicado: (2008)

Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma
por: Xun, Yang, et al.
Publicado: (2021)

Co‐administration of Antimicrobial Peptides Enhances Toll‐like Receptor 4 Antagonist Activity of a Synthetic Glycolipid
por: Facchini, Fabio A., et al.
Publicado: (2018)

Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes
por: Patinote, Cindy, et al.
Publicado: (2020)

Toll-like receptor (TLRs) agonists and antagonists for COVID-19 treatments
por: Liu, Zhi-Mei, et al.
Publicado: (2022)

Synthesis of Enantiopure 10-Nornaltrexones in the Search for Toll-like Receptor 4 Antagonists and Opioid Ligands
por: Selfridge, Brandon R., et al.
Publicado: (2014)

The role of toll-like receptor 4 in tumor microenvironment
por: Li, Jing, et al.
Publicado: (2017)

Computational Approaches to Toll-Like Receptor 4 Modulation
por: Billod, Jean-Marc, et al.
Publicado: (2016)

Toll-like Receptor 4 in Acute Kidney Injury
por: Vallés, Patricia G., et al.
Publicado: (2023)

Ulvan Activates Chicken Heterophils and Monocytes Through Toll-Like Receptor 2 and Toll-Like Receptor 4
por: Guriec, Nathalie, et al.
Publicado: (2018)

Evidence for Activation of Toll-Like Receptor and Receptor for Advanced Glycation End Products in Preterm Birth
por: Noguchi, Taketoshi, et al.
Publicado: (2010)

Toll-Like Receptors in Atherosclerosis
por: Falck-Hansen, Mika, et al.
Publicado: (2013)

Toll-like Receptors and Thrombopoiesis
por: Tang, Xiaoqin, et al.
Publicado: (2023)

Toll-like receptor activation by helminths or helminth products to alleviate inflammatory bowel disease
por: Sun, ShuMin, et al.
Publicado: (2011)

Expression and activation of toll-like receptor 3 and toll-like receptor 4 on human corneal epithelial and conjunctival fibroblasts
por: Erdinest, Nir, et al.
Publicado: (2014)

Obesity, Inflammation, Toll-Like Receptor 4 and Fatty Acids
por: Rogero, Marcelo Macedo, et al.
Publicado: (2018)

Links between Toll-like receptor 4 and breast cancer
por: Ahmed, Abubakr, et al.
Publicado: (2013)

Emerging role of Toll-like receptor 4 in hepatocellular carcinoma
por: Yang, Jing, et al.
Publicado: (2015)

The emerging role of Toll-like receptor 4 in myocardial inflammation
por: Yang, Y, et al.
Publicado: (2016)

Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation
por: Guiducci, Cristiana, et al.
Publicado: (2006)

Novel Toll-like receptor-4 antagonist (+)-naloxone protects mice from inflammation-induced preterm birth
por: Chin, Peck Yin, et al.
Publicado: (2016)

Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9
por: Kandimalla, Ekambar R., et al.
Publicado: (2013)

Natural Modulators of Endosomal Toll-Like Receptor-Mediated Psoriatic Skin Inflammation
por: Lai, Chao-Yang, et al.
Publicado: (2017)

Toll-Like Receptors in Angiogenesis
por: Grote, Karsten, et al.
Publicado: (2011)

Toll-like receptors and NOD-like receptors in rheumatic diseases
por: McCormack, William J, et al.
Publicado: (2009)

Toll-like receptors in lupus nephritis
por: Devarapu, Satish Kumar, et al.
Publicado: (2018)

Toll-like receptor downstream signaling
por: Kawai, Taro, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_tg41jqgprkb348ojv11m2vh9r9